First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study
El Zarif T, Semaan K, Xie W, Eid M, Zarba M, Issa W, Zhang T, Nguyen C, Alva A, Fahey C, Beckermann K, Karam J, Campbell M, Procopio G, Stellato M, Buti S, Zemankova A, Melichar B, Massari F, Mollica V, Venugopal B, Ebrahimi H, de Velasco G, Gurney H, De Giorgi U, Parikh O, Winquist E, Master V, Garcia A, Cutuli H, Ferguson T, Gross-Goupil M, Baca S, Pal S, Braun D, McKay R, Heng D, Choueiri T. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. European Urology 2024, 86: 503-512. PMID: 39147674, DOI: 10.1016/j.eururo.2024.07.016.Peer-Reviewed Original ResearchRenal cell carcinomaProgression-free survivalInternational Metastatic RCC Database ConsortiumRecurrent renal cell carcinomaTreatment-related adverse eventsSystemic therapyAdjuvant pembrolizumabOverall survivalCell carcinomaClinical outcomesIO therapyAdjuvant immunotherapyAdverse eventsVascular endothelial growth factor-targeted therapyDetect occult metastatic diseaseOutcomes of first-lineFirst-line systemic therapyFavorable-risk diseaseIO-based regimensOccult metastatic diseaseMedian follow-upKaplan-Meier methodShort follow-up periodFollow-up periodInternational multicenter study45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma
Choueiri T, Powles T, Braun D, Fong L, George D, Haas N, McDermott D, Shuch B, Gurney H, Meehan R, Posadas T, Wu S, Elfiky A, Motzer R. 45 INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma. The Oncologist 2024, 29: s15-s15. PMCID: PMC11301864, DOI: 10.1093/oncolo/oyae181.022.Peer-Reviewed Original ResearchRenal cell carcinomaWeeks prior to randomizationAdverse eventsAdjuvant treatmentCell carcinomaResection of metastatic lesionsAdjuvant treatment of patientsPD-1 inhibitor pembrolizumabIncreased risk of recurrenceAdjuvant treatment of renal cell carcinomaTreatment of renal cell carcinomaActivity of pembrolizumabStage III/IV melanomaStudy of pembrolizumabDisease-free survivalMetastasis-free survivalPhase 2 trialRisk of recurrenceDouble-blind studyTreatment of patientsNovel combination strategiesDose of treatmentAdjuvant pembrolizumabAdjuvant settingInhibitor pembrolizumab